SHOULDER INNOVATIONS INC

Gilde Healthcare’s gradual sale of 7,338 shares of Shoulder Innovations reveals a cautious approach amid rising Q2 revenue and market volatility—track the trend for investor insight.

Gilde Healthcare’s recent sale of 110k SIII shares near $23 raises questions, yet a fresh buy‑back plan suggests long‑term upside. Discover what it means for investors.

Insider sales at SHOULDER INNOVATIONS show a planned, risk‑mitigated move by COO Matthew Fraser—not a bearish signal, but a cue to watch future filings and market sentiment.

CEO Ball Robert Joseph buys 10,000 shares at $2.48 on a capital‑raise, signaling confidence in Shoulder Innovations’ expansion and potential upside for investors.

Insider CFO buys 13,264 shares at $2.48, converting options to cash before a crucial board vote – signals confidence but raises volatility risks for investors.

CEO Robert Joseph’s $2.48 insider buy fuels confidence in Shoulder Innovations as the stock edges toward a rebound.